Crispr Therapeutics shares tumble after significant earnings miss
FORT WORTH, TX—Thomas E. Ferguson, President and CEO of AZZ Inc (NYSE:AZZ), recently sold 18,851 shares of the company’s common stock. The transaction, which took place on May 5, 2025, was executed at a weighted average price of $89.91 per share, totaling approximately $1.69 million. The sale comes as AZZ, a $2.7 billion market cap industrial company, demonstrates strong market performance with a 20% return over the past year and maintains a "GOOD" financial health rating according to InvestingPro analysis.
Following the sale, Ferguson retains ownership of 192,607 shares in the company. This transaction was disclosed in a filing with the Securities and Exchange Commission, highlighting Ferguson’s role as both a director and officer at AZZ Inc. According to InvestingPro data, the stock currently trades at a high P/E multiple of 50x, while analysts maintain a bullish outlook with a consensus target suggesting potential upside. For deeper insights into AZZ’s valuation and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, AZZ Incorporated reported its Q4 2025 earnings, achieving expected earnings per share (EPS) of $0.98 but falling short on revenue with $351.9 million against a forecast of $375.63 million. Despite the revenue miss, the company experienced a 26.8% increase in full-year net income, reaching $128.8 million, and recorded a 2.6% rise in full-year sales to $1.578 billion. Jefferies analyst Laurence Alexander maintained a Buy rating for AZZ but adjusted the stock price target from $110.00 to $99.00, citing the company’s alignment with EPS expectations and a positive outlook for 2025. Alexander noted that AZZ’s Metal Coatings segment is expected to see demand growth, driven by infrastructure and data center projects, while the Precoat segment may face challenges due to trade policy uncertainties. AZZ plans strategic investments, including potential acquisitions, to enhance its growth and diversification. The company also aims to reduce debt by over $165 million in fiscal 2026, alongside capital expenditures of $60 to $80 million. Additionally, AZZ’s management highlighted their focus on organic growth and strategic investments, with projections for fiscal 2026 sales between $1.625 billion and $1.725 billion, and adjusted EPS guidance of $5.50 to $6.10.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.